Video

Dr. Ruan on the Utility of Molecular Profiling in Mantle Cell Lymphoma

Jia Ruan, MD, PhD, discusses ​the utility of molecular profiling in mantle cell lymphoma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses ​the utility of molecular profiling in mantle cell lymphoma (MCL).

Obtaining a patient's genetic mutation profile can be a useful risk-stratification tool, says Ruan. For example, TP53 mutations or deletions can inform a patient’s prognosis and likelihood of response to standard therapy.

Prospective studies using chemoimmunotherapy ​demonstrated​ less favorable survival data for patients with TP53 aberrations compared with patients who do not harbor TP53 aberrations, explains Ruan. Although chemoimmunotherapy may be offered to these patients, ​alternative options should be considered ​early on in cases of no response or early relapse. 

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity